CTIS2023-509452-34-00进行中（未招募）1 期
A Phase IIa Open Label, Dose-Finding, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients with Peripheral Arterial Disease (PAD) - 2023-509452-34-00
Vivacell Biotechnology Espana S.L.0 个研究点目标入组 30 人开始时间: 2024年2月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male and female adults aged = 50 to = 85 years at the time of consent, Willing and able to provide informed consent and capable of understanding and complying with the protocol;, Subjects classified as critical limb ischemia (CLI) Rutherford Category 2 or 3 (moderate or severe) claudication (Appendix 1);, Diabetes mellitus type 2, Glycosylated haemoglobin (HbA1c) < 9%, In case of treatment for PAD, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance), A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a) Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause) b) Of childbearing potential and agrees to use a highly effective method of contraception consistently as defined in this protocol during the treatment period and for at least 28 days after the last dose of study treatment, A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for approximately 90 days after the last dose of study treatment and refrains from donating sperm during this period
排除标准
- •CLI Rutherford other than Category 2 or 3, Evidence of moderate to severe hepatocellular dysfunction according to the Investigator, Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema Pallidum, Subjects who may not be healthy enough to successfully complete all protocol requirements, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator: For example: Concurrent severe congestive heart failure (New York Heart Association Classes III and IV); Life-threatening ventricular arrhythmias, unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration), and/or myocardial infarction within four weeks before screening; Coronary artery bypass grafting or percutaneous coronary intervention within one month before screening; A renal and/or carotid revascularization procedure within one month of screening; Transient ischemic attack within three months prior to screening; Deep vein thrombosis within three months prior to screening; Subjects with immunocompromised conditions, organ transplant recipients and/or subjects in need of immunosuppressive therapy; Neurological dementia (i.e., Alzheimer’s Disease), Current or prior participation in a clinical trial within 3 months of first investigational product administration or 5 times the half-life of the prior investigational product, whichever is longer, Concomitant medication that could cause drug-interactions as defined in the appropriate section of the protocol, (Section 6.7)., History of malignancy with the following exceptions: basal cell carcinoma, cutaneous squamous cell carcinoma or cervical carcinoma in situ resolved > 1 year prior to screening, Use of cannabis products up to 28 days prior to dosing and during the study, Suspected hypersensitivity to cannabinoids or any of the inactive ingredients of Etrinabdione Oral Solution: corn oil and Maisine® CC, Confirmed diagnosis of albinism, Moderate or severe drug or alcohol abuse within the past year and during the study (as defined by the investigator), Planned surgical or endovascular revascularization on the index leg within the next 12 months;, Female participant is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding at any point during the study and for 28 days after last investigational product administration. Not willing to follow the guidance for contraception methods as per protocol, Male participant does not agree to use acceptable contraception during the treatment period and for approximately 90 days after the last dose of study treatment or planning to donate sperm during the same period, Any finding that in the view of the investigator would compromise the safety of the patient or affect his/her ability to adhere to the protocol visit schedule or fulfil study requirements including self-administration, Uncontrolled or untreated proliferative retinopathy;, Failed surgical or endovascular revascularization on the index leg within 10 days prior to screening, Amputation at or above the talus on the index l, Planned major amputation within the first month after randomiz, On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new treatments (not standard of care) to the ind
研究者
相似试验
进行中（未招募）
1 期
A Trial of Lu AG13909 in Adult Participants with Cushing’s DiseaseCushing's DiseaseMedDRA version: 20.0Level: LLTClassification code: 10011651Term: Cushing's disease Class: 10014698CTIS2023-504733-53-00H. Lundbeck A/S18
进行中（未招募）
1 期
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancerlocally advanced/metastatic prostate cancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864CTIS2024-511038-11-00Debiopharm International SA60
进行中（未招募）
不适用
A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteersProphyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis)Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive red blood cells.MedDRA version: 9.1Level: LLTClassification code 10019513Term: Hemolytic disease of fetus or newborn, due to isoimmunizationMedDRA version: 9.1Level: LLTClassification code 10044360Term: Transfusion with incompatible bloodEUCTR2009-011017-24-DEFB Biotechnologies
进行中（未招募）
1 期
A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 in cancer patientsSelected solid tumours (melanoma, pancreatic ductal adenocarcinoma, ovarian cancer, colorectal adenocarcinoma, hepatocellular carcinoma, gallbladder cancer and cholangiocarcinoma, uveal melanoma, gastric adenocarcinoma (including GE junction) and estrogen receptor positive breast cancer).MedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2018-002732-24-FRFaron Pharmaceuticals Ltd650
进行中（未招募）
1 期
A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 in cancer patientsSelected solid tumours (melanoma, pancreatic ductal adenocarcinoma,ovarian cancer, colorectal adenocarcinoma, hepatocellular carcinoma,gallbladder cancer and cholangiocarcinoma, uveal melanoma, gastricadenocarcinoma (including GE junction) and estrogen receptor positivebreast cancer).MedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2018-002732-24-NLFaron Pharmaceuticals Ltd650